Biotech startup Kite Pharma has raised $35m for cancer-fighting technologies in a series A round backed by a syndicate of investors.

The Los Angeles-based startup announced that it has closed $20m in new funds, as well as converting $15m in outstanding promissory notes into series A preferred stock. Life science VC Alta Partners, VC firm Pontifax and Commercial Street Capital were joined by Kite’s founder Arie Belldegrun and investment firm TPG Group co-founder David Bonderman for the round.

As part…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?